Logo image of PTPI

PETROS PHARMACEUTICALS INC (PTPI) Stock Fundamental Analysis

NASDAQ:PTPI - Nasdaq - US71678J2096 - Common Stock - Currency: USD

0.125  -0.01 (-5.59%)

After market: 0.127 +0 (+1.6%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to PTPI. PTPI was compared to 194 industry peers in the Pharmaceuticals industry. PTPI has a bad profitability rating. Also its financial health evaluation is rather negative. PTPI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PTPI had negative earnings in the past year.
In the past year PTPI has reported a negative cash flow from operations.
In the past 5 years PTPI always reported negative net income.
PTPI had negative operating cash flow in 4 of the past 5 years.
PTPI Yearly Net Income VS EBIT VS OCF VS FCFPTPI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M

1.2 Ratios

PTPI's Return On Assets of -144.12% is on the low side compared to the rest of the industry. PTPI is outperformed by 84.32% of its industry peers.
Looking at the Return On Equity, with a value of -956.75%, PTPI is doing worse than 84.32% of the companies in the same industry.
Industry RankSector Rank
ROA -144.12%
ROE -956.75%
ROIC N/A
ROA(3y)-38.68%
ROA(5y)-40.24%
ROE(3y)-85.33%
ROE(5y)-155.84%
ROIC(3y)N/A
ROIC(5y)N/A
PTPI Yearly ROA, ROE, ROICPTPI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 500 1K 1.5K

1.3 Margins

PTPI has a better Gross Margin (74.74%) than 81.08% of its industry peers.
In the last couple of years the Gross Margin of PTPI has declined.
The Profit Margin and Operating Margin are not available for PTPI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.69%
GM growth 5Y-2.77%
PTPI Yearly Profit, Operating, Gross MarginsPTPI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

0

2. Health

2.1 Basic Checks

PTPI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PTPI has more shares outstanding
Compared to 5 years ago, PTPI has more shares outstanding
The debt/assets ratio for PTPI has been reduced compared to a year ago.
PTPI Yearly Shares OutstandingPTPI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M 2.5M
PTPI Yearly Total Debt VS Total AssetsPTPI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -10.13, we must say that PTPI is in the distress zone and has some risk of bankruptcy.
PTPI's Altman-Z score of -10.13 is on the low side compared to the rest of the industry. PTPI is outperformed by 76.22% of its industry peers.
PTPI has a Debt/Equity ratio of 1.58. This is a high value indicating a heavy dependency on external financing.
PTPI has a worse Debt to Equity ratio (1.58) than 77.84% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.58
Debt/FCF N/A
Altman-Z -10.13
ROIC/WACCN/A
WACC6.25%
PTPI Yearly LT Debt VS Equity VS FCFPTPI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 10M -10M 20M 30M

2.3 Liquidity

PTPI has a Current Ratio of 0.85. This is a bad value and indicates that PTPI is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of PTPI (0.85) is worse than 89.73% of its industry peers.
A Quick Ratio of 0.74 indicates that PTPI may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.74, PTPI is doing worse than 87.03% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.85
Quick Ratio 0.74
PTPI Yearly Current Assets VS Current LiabilitesPTPI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

5

3. Growth

3.1 Past

PTPI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -48.10%.
PTPI shows a strong growth in Revenue. In the last year, the Revenue has grown by 46.16%.
Measured over the past years, PTPI shows a very negative growth in Revenue. The Revenue has been decreasing by -16.15% on average per year.
EPS 1Y (TTM)-48.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.13%
Revenue 1Y (TTM)46.16%
Revenue growth 3Y-15.24%
Revenue growth 5Y-16.15%
Sales Q2Q%-5.87%

3.2 Future

Based on estimates for the next years, PTPI will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.87% on average per year.
The Revenue is expected to grow by 23.86% on average over the next years. This is a very strong growth
EPS Next Y58.64%
EPS Next 2Y33.73%
EPS Next 3Y21.34%
EPS Next 5Y14.87%
Revenue Next Year-29.45%
Revenue Next 2Y-15.69%
Revenue Next 3Y-10.88%
Revenue Next 5Y23.86%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PTPI Yearly Revenue VS EstimatesPTPI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
PTPI Yearly EPS VS EstimatesPTPI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PTPI. In the last year negative earnings were reported.
Also next year PTPI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PTPI Price Earnings VS Forward Price EarningsPTPI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PTPI Per share dataPTPI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3 -4

4.3 Compensation for Growth

PTPI's earnings are expected to grow with 21.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.73%
EPS Next 3Y21.34%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PTPI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PETROS PHARMACEUTICALS INC

NASDAQ:PTPI (2/21/2025, 8:00:01 PM)

After market: 0.127 +0 (+1.6%)

0.125

-0.01 (-5.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners2.16%
Inst Owner Change-40.87%
Ins Owners6.83%
Ins Owner Change0%
Market Cap1.25M
Analysts82.86
Price Target1.02 (716%)
Short Float %7.83%
Short Ratio0.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.14%
Min EPS beat(2)-79.18%
Max EPS beat(2)52.89%
EPS beat(4)1
Avg EPS beat(4)-35.9%
Min EPS beat(4)-102.26%
Max EPS beat(4)52.89%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)7.53%
Min Revenue beat(2)-0.25%
Max Revenue beat(2)15.32%
Revenue beat(4)2
Avg Revenue beat(4)69.07%
Min Revenue beat(4)-6.35%
Max Revenue beat(4)267.58%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)59.26%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.12
P/FCF N/A
P/OCF N/A
P/B 0.4
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.88
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS1.02
BVpS0.31
TBVpS-0.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -144.12%
ROE -956.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.74%
FCFM N/A
ROA(3y)-38.68%
ROA(5y)-40.24%
ROE(3y)-85.33%
ROE(5y)-155.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.69%
GM growth 5Y-2.77%
F-Score4
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 1.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.85
Quick Ratio 0.74
Altman-Z -10.13
F-Score4
WACC6.25%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.13%
EPS Next Y58.64%
EPS Next 2Y33.73%
EPS Next 3Y21.34%
EPS Next 5Y14.87%
Revenue 1Y (TTM)46.16%
Revenue growth 3Y-15.24%
Revenue growth 5Y-16.15%
Sales Q2Q%-5.87%
Revenue Next Year-29.45%
Revenue Next 2Y-15.69%
Revenue Next 3Y-10.88%
Revenue Next 5Y23.86%
EBIT growth 1Y-74.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y70.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.16%
OCF growth 3YN/A
OCF growth 5YN/A